Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

HLA and microtubule-associated protein tau H1 haplotype associations in anti-IgLON5 disease

  • Gaig, Carles|||0000-0002-7113-8125
  • Ercilla, Guadalupe
  • Daura i Ribera, Xavier|||0000-0001-9235-6730
  • Ezquerra, Mario|||0000-0003-3246-6641
  • Fernández-Santiago, Rubén|||0000-0002-4582-0702
  • Palou, Eduard|||0000-0003-1544-1485
  • Sabater, Lidia
  • Höftberger, Romana|||0000-0002-5769-1100
  • Heidbreder, Anna
  • Högl, Birgit
  • Iranzo, Alex|||0000-0002-5618-8271
  • Santamaria Cano, Joan|||0000-0003-0879-4135
  • Dalmau, Josep|||0000-0001-5856-2813
  • Graus Ribas, Francesc|||0000-0002-8924-8322
We investigated the associations with HLA and microtubule-associated protein tau (MAPT) H1 haplotype in anti-IgLON5 disease, a recently identified disorder characterized by gait instability, brainstem dysfunction, and a prominent sleep disorder in association with IgLON5 antibodies and pathologic findings of a novel neuronal-specific tauopathy. We compared the HLA alleles and MAPT H1/H1 genotype of 35 patients with anti-IgLON5 with healthy controls. The on-line server tool NetMHCIIpan 3.1 was used to predict the IgLON5 peptide binding to HLA Class II molecules. The HLA-DRB1*10:01-DQB1*05:01 haplotype was overrepresented in patients with anti-IgLON5 disease (OR = 54.5; 95% CI: 22.2-133.9, p < 0.0001). In addition, HLA-DQA was genotyped in 27 patients, and 25 (92.6%) of them had DQ molecules composed by DQA1*01 and DQB1*05 chains compared with 148/542 (27.3%) controls (OR = 43.9; 95% CI: 10.4-185.5, p < 0.0001). Patients DRB1*10:01 positive developed more frequently sleep or bulbar symptoms than those carrying other HLA alleles (70.0% vs 26.7%; p = 0.011). Prediction algorithms identified 2 IgLON5 peptides (1 located in the signal sequence) that showed strong binding to HLA-DRB1*10:01 and other HLA-DRB1, but not to HLA-DQA and HLA-DQB molecules. The MAPT H1/H1 homozygous genotype was present in 20/24 (83.3%) anti-IgLON5 Caucasian patients compared with 54/116 (46.5%) healthy controls (p = 0.0007). The robust association of anti-IgLON5 disease with distinct HLA Class II molecules supports a primary autoimmune origin. The significant association of MAPT H1 haplotype also suggests that an underlying neurodegenerative process could be involved in anti-IgLON5 disease.